Ki-67 labeling index as a predictor of response to neoadjuvant chemotherapy in breast cancer
出版年份 2019 全文链接
标题
Ki-67 labeling index as a predictor of response to neoadjuvant chemotherapy in breast cancer
作者
关键词
-
出版物
JAPANESE JOURNAL OF CLINICAL ONCOLOGY
Volume -, Issue -, Pages -
出版商
Oxford University Press (OUP)
发表日期
2019-01-16
DOI
10.1093/jjco/hyz012
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- ER, PgR, Ki67, p27Kip1, and histological grade as predictors of pathological complete response in patients with HER2-positive breast cancer receiving neoadjuvant chemotherapy using taxanes followed by fluorouracil, epirubicin, and cyclophosphamide concomitant with trastuzumab
- (2015) Sasagu Kurozumi et al. BMC CANCER
- Pathological complete response after neoadjuvant chemotherapy is an independent predictive factor irrespective of simplified breast cancer intrinsic subtypes: a landmark and two-step approach analyses from the EORTC 10994/BIG 1-00 phase III trial
- (2014) H. Bonnefoi et al. ANNALS OF ONCOLOGY
- Ki-67 as a Predictor of Response to Neoadjuvant Chemotherapy in Breast Cancer Patients
- (2014) Kwan Il Kim et al. Journal of Breast Cancer
- Clinical significance of pretherapeutic Ki67 as a predictive parameter for response to neoadjuvant chemotherapy in breast cancer; is it equally useful across tumor subtypes?
- (2014) Aiko Sueta et al. SURGERY
- Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013
- (2013) A. Goldhirsch et al. ANNALS OF ONCOLOGY
- Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update
- (2013) Antonio C. Wolff et al. JOURNAL OF CLINICAL ONCOLOGY
- An International Ki67 Reproducibility Study
- (2013) Mei-Yin C. Polley et al. JNCI-Journal of the National Cancer Institute
- A common language in neoadjuvant breast cancer clinical trials: proposals for standard definitions and endpoints
- (2012) Debora Fumagalli et al. LANCET ONCOLOGY
- Pathological Complete Response and Accelerated Drug Approval in Early Breast Cancer
- (2012) Tatiana M. Prowell et al. NEW ENGLAND JOURNAL OF MEDICINE
- Recommendations from an International Consensus Conference on the Current Status and Future of Neoadjuvant Systemic Therapy in Primary Breast Cancer
- (2011) Manfred Kaufmann et al. ANNALS OF SURGICAL ONCOLOGY
- Ki67, chemotherapy response, and prognosis in breast cancer patients receiving neoadjuvant treatment
- (2011) Peter A Fasching et al. BMC CANCER
- Pathologic Complete Response After Neoadjuvant Chemotherapy Plus Trastuzumab Predicts Favorable Survival in Human Epidermal Growth Factor Receptor 2–Overexpressing Breast Cancer: Results From the TECHNO Trial of the AGO and GBG Study Groups
- (2011) Michael Untch et al. JOURNAL OF CLINICAL ONCOLOGY
- Effect of neoadjuvant anthracycline–taxane-based chemotherapy in different biological breast cancer phenotypes: overall results from the GeparTrio study
- (2010) Jens Huober et al. BREAST CANCER RESEARCH AND TREATMENT
- Impact of treatment characteristics on response of different breast cancer phenotypes: pooled analysis of the German neo-adjuvant chemotherapy trials
- (2010) Gunter von Minckwitz et al. BREAST CANCER RESEARCH AND TREATMENT
- Immunohistochemical surrogate markers of breast cancer molecular classes predicts response to neoadjuvant chemotherapy
- (2010) Rohit Bhargava et al. CANCER
- Current and emerging biomarkers in breast cancer: prognosis and prediction
- (2010) Marion T Weigel et al. ENDOCRINE-RELATED CANCER
- Neoadjuvant Treatment With Trastuzumab in HER2-Positive Breast Cancer: Results From the GeparQuattro Study
- (2010) Michael Untch et al. JOURNAL OF CLINICAL ONCOLOGY
- Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort
- (2010) Luca Gianni et al. LANCET
- Evaluation of ER, PgR, HER-2, Ki-67, cyclin D1, and nm23-H1 as predictors of pathological complete response to neoadjuvant chemotherapy for locally advanced breast cancer
- (2010) Xi-ru Li et al. MEDICAL ONCOLOGY
- Clinical significance of Ki-67 in neoadjuvant chemotherapy for primary breast cancer as a predictor for chemosensitivity and for prognosis
- (2009) Reiki Nishimura et al. Breast Cancer
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreDiscover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversation